Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin

Authors

  • Norah A. Terrault M.D.,

    1. Department of Medicine University of Virginia Health Sciences Center, Charlotesville, VA
    2. Department of Veteran's Administration Medical Center San Francisco
    3. University of California, San Francisco, CA
    Search for more papers by this author
  • Shuan Zhou,

    1. Department of Medicine University of Virginia Health Sciences Center, Charlotesville, VA
    2. Department of Veteran's Administration Medical Center San Francisco
    3. University of California, San Francisco, CA
    Search for more papers by this author
  • Robert W. McCory,

    1. Department of Surgery, University of Virginia Health Sciences Center, Charlotesville, VA
    Search for more papers by this author
  • Timothy L. Pruett,

    1. Department of Surgery, University of Virginia Health Sciences Center, Charlotesville, VA
    Search for more papers by this author
  • John R. Lake,

    1. Department of Medicine University of Virginia Health Sciences Center, Charlotesville, VA
    2. University of California, San Francisco, CA
    Search for more papers by this author
  • John P. Roberts,

    1. Department of Surgery, University of Virginia Health Sciences Center, Charlotesville, VA
    2. University of California, San Francisco, CA
    Search for more papers by this author
  • Nancy L. Ascher,

    1. Department of Surgery, University of Virginia Health Sciences Center, Charlotesville, VA
    2. University of California, San Francisco, CA
    Search for more papers by this author
  • Teresa L. Wright

    Corresponding author
    1. Department of Medicine University of Virginia Health Sciences Center, Charlotesville, VA
    2. Department of Veteran's Administration Medical Center San Francisco
    3. University of California, San Francisco, CA
    • 111B, GI Unit, Veterans Administration Medical Center, 4150 Clement St., San Francisco, CA 94121. Fax: (415) 750-2196
    Search for more papers by this author

Abstract

Mutations in the “a” determinant of the surface gene have been associated with failure of hepatitis B immunoglobulin (HBIg) prophylaxis. We compared sequences from the surface and polymerase regions of hepatitis B virus (HBV) from 4 patients who failed high-dose HBIg therapy with two control groups: HBIg-treated patients who remained hepatitis B surface antigen (HBsAg)-negative (n = 4) and HBV-infected transplant recipients who never received HBIg (n = 4). Mutations within the surface and overlapping polymerase region were more common in patients failing HBIg than controls (P = .03), and mutations in the region of the “a” determinant were present only in patients failing HBIg. To examine the relationship between HBIg failure and duration of therapy, five additional treatment failures from a second transplantation center were sequenced (total with HBIg failure = 9). Mutations in the “a” determinant developed in 1 of 3 patients receiving HBIg for less than 6 months compared with 5 of 6 patients failing HBIg after 6 months of therapy (P = .23). The most frequently identified amino acid substitution was glycine to arginine at position 145 (present in 4 of 6 patients who failed HBIg after at least 6 months of treatment). A unique mutation within the YMDD motif (methionine to leucine) was present in 1 patient who failed HBIg treatment and who received a short course of ganciclovir. We conclude that the emergence of mutations in the “a” determinant accounts for some, but not all, treatment failures in patients receiving HBIg prophylaxis. Mutations in other regions of the S gene were more common in patients failing HBIg than controls, suggesting that domains other than the “a” determinant may be important.

Ancillary

Advertisement